Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer

Modern Pathology

Volumn 18, Issue 7, 2005, Pages 886-890

  Eichelberger, Lori E ^a   Koch, Michael O ^a   Eble, John N ^a   Ulbright, Thomas M ^a   Juliar, Beth E ^a   Cheng, Liang ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Neoplasm; Prostate; Prostatectomy; PSA recurrence; TNM staging; Tumor diameter; Tumor length; Tumor volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CONFIDENCE INTERVAL; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT DISEASE; RISK FACTOR; TUMOR VOLUME;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 23044497683     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800405     Document Type: Article

References (22)

1. Renshaw AA. Correlation of gross morphologic features with histologic features in radical prostatectomy specimens. Am J Clin Pathol 1998;110:38-42.
2. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998;90:233-237.
3. Greene DR, Egawa S, Neerhut G, et al. The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J Urol 1991;146:1069-1076.
4. Arora R, Koch MO, Eble JN, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004;100:2362-2366.
5. Renshaw AA, Chang H, D'Amico AV. Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. Am J Clin Pathol 1997;107: 704-708.
6. Eichelberger LE, Koch MO, Daggy JK, et al. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am J Clin Pathol 2003;120:386-391.
7. Babaian RJ, Troncoso P, Bhadkamkar VA, et al. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 2001;91: 1414-1422.
8. van den Ouden D, Bentvelsen FM, Boeve ER, et al. Positive margins after radical prostatectomy: correlation with lacal recurrence and distant progression. Br J Urol 1993;72:489-494.
9. Koch MO, Foster RS, Bell B, et al. Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. J Urol 2000;164: 749-753.
10. Eichelberger LE, Cheng L. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. Cancer 2004;100: 2573-2576.
11. Fleming ID, Cooper JS, Henson DE, et al. American Joint Committee on Cancer Staging Manual. Lippincott Raven: Philadelphia, 1997, pp 219-222.
12. Gleason DF, Mellingerr GT. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical stage. J Urol 1974;111:58-64.
13. Bostwick DG. Neoplasms of the prostate. In: Bostwick DG, Eble JN (eds). Urologic Surgical Pathology. Mosby: St Louis, 1997, pp 343-422.
14. Cheng L, Slezak J, Bergstralh EJ, et al. Preoperative prediction of surgical margin status in prostate cancer patients treated by radical prostatectomy. J Clin Oncol 2000;18:2862-2868.
15. Sakamoto Y, Ishiguro M, Kitagawa G. Akaike Information Criterion Statistics. D. Reidel Publishing Company: The Netherlands, 1986.
16. Stamey T, McNeal J, Yemoto C, et al. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281:1395-1400.
17. Renshaw AA, Richie JO, Loughlin KR, et al. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 1998;83:748-752.
18. Renshaw AA, Richie JP, Loughlin KR, et al. Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens. Am J Clin Pathol 1999;111:641-644.
19. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. Urol Clin N Am 2001;28:555-565.
20. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
21. Obek C, Sadek S, Lai S, et al. Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology 1999;54:682-688.
22. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998;160:2428-2434.